Literature DB >> 23340301

HIC1 modulates prostate cancer progression by epigenetic modification.

Jianghua Zheng1, Jinglong Wang, Xueqing Sun, Mingang Hao, Tao Ding, Dan Xiong, Xiumin Wang, Yu Zhu, Gang Xiao, Guangcun Cheng, Meizhong Zhao, Jian Zhang, Jianhua Wang.   

Abstract

PURPOSE: Prostate cancer is the second leading cause of cancer deaths among men in Western counties, which has also occurred in Chinese male with markedly increasing incidence in recent years. Although the mechanism underlying its progression still remains unclear, epigenetic modifications are important ethological parameters. The purpose of this study is to determine the methylation status and function of hypermethylatioted in cancer 1 (HIC1) in prostate cancer progression. EXPERIMENTAL
DESIGN: The methylation status of HIC1 promoter was assayed in cell lines, tissues, and plasma of patients with prostate cancer by using methylation-specific PCR and bisulfate sequencing PCR. The ability of HIC1 to regulate proliferation, migration, and invasion was assessed by MTT, scratch-healing assay, and reconstituted extracellular matrices in porous culture chambers. Tumorigenesis, metastases, and bone destruction were analyzed in mice bearing prostate cancer cells restoring HIC1 by using Xenogen IVIS with radiographic system and small-animal positron emission tomography computed tomographic images. Microarrays were searched for genes that had correlated expression with HIC1 mRNA. Reporter gene assays were used to determine whether HIC1 affected the expression of CXCR7, and chromatin immunoprecipitation was used to determine whether HIC1 bound to CXCR7 promoters. All P values were determined using 2-sided tests.
RESULTS: The methylation status of 11 CpG sites within HIC1 promoter was abundantly methylated in cell lines, tissues, and plasma of patients with prostate cancer compared with those of respective normal controls. Restoring HIC1 expression in prostate cancer cells markedly inhibited proliferation, migration, and invasion and induced the apoptosis in these cells. Moreover, mice bearing prostate cancer-restoring HIC1 cells had a marked effect on reducing tumor growth, multiple tissue metastases, and bone destruction. Notably, we also identified that the chemokine receptor CXCR7 is a direct downstream target gene of HIC1. Finally, we showed that CXCR7 promoter in prostate cancer cells is negatively regulated by HIC1, which may be responsible for prostate cancer progression.
CONCLUSIONS: Our data show for the first time that hypermethylation of HIC1 promoter results in loss of its repressive function, responsible for prostate cancer progression and invasion. These findings suggest that therapies targeting epigenetic events regulating HIC1 expression may provide a more effective strategy for prostate cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340301     DOI: 10.1158/1078-0432.CCR-12-2888

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

Review 1.  Epigenetic alterations in osteosarcoma: promising targets.

Authors:  Binghao Li; Zhaoming Ye
Journal:  Mol Biol Rep       Date:  2014-02-06       Impact factor: 2.316

2.  Expression of chemokine receptor CXCR7 in colorectal carcinoma and its prognostic significance.

Authors:  Dan Yang; Tingting Dai; Lijun Xue; Xiaobei Liu; Bo Wu; Jian Geng; Xiaobei Mao; Rui Wang; Longbang Chen; Xiaoyuan Chu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Expression of the tumor suppressor gene hypermethylated in cancer 1 in laryngeal carcinoma.

Authors:  Jarosław Markowski; Aleksander L Sieroń; Katarzyna Kasperczyk; Monika Ciupińska-Kajor; Aleksandra Auguściak-Duma; Wirginia Likus
Journal:  Oncol Lett       Date:  2015-02-25       Impact factor: 2.967

4.  Bmi-1 expression modulates non-small cell lung cancer progression.

Authors:  Dan Xiong; Yunlin Ye; Yujie Fu; Jinglong Wang; Bohua Kuang; Hongbo Wang; Xiumin Wang; Lidong Zu; Gang Xiao; Mingang Hao; Jianhua Wang
Journal:  Cancer Biol Ther       Date:  2015-04-16       Impact factor: 4.742

5.  Small extracellular vesicle-associated miR-6068 promotes aggressive phenotypes of prostate cancer through miR-6068/HIC2/SIRT1 axis.

Authors:  Mohamed S A Gaballah; Hamdy E A Ali; Zeinab A Hassan; Shahenda Mahgoub; Hamid I Ali; Johng S Rhim; Mourad Zerfaoui; Khalid A El Sayed; David Stephen; Paul W Sylvester; Zakaria Y Abd Elmageed
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

6.  HIC1 modulates uveal melanoma progression by activating lncRNA-numb.

Authors:  Guangcun Cheng; Jie He; Leilei Zhang; Shengfang Ge; He Zhang; Xianqun Fan
Journal:  Tumour Biol       Date:  2016-07-23

Review 7.  Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics.

Authors:  Brian R Rood; Dominique Leprince
Journal:  Expert Opin Ther Targets       Date:  2013-04-09       Impact factor: 6.902

Review 8.  The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses.

Authors:  Joseph A Westrich; Daniel W Vermeer; Paul L Colbert; William C Spanos; Dohun Pyeon
Journal:  Mol Carcinog       Date:  2020-03-24       Impact factor: 4.784

9.  HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk.

Authors:  Yingying Wang; Xiaoling Weng; Luoyang Wang; Mingang Hao; Yue Li; Lidan Hou; Yu Liang; Tianqi Wu; Mengfei Yao; Guowen Lin; Yiwei Jiang; Guohui Fu; Zhaoyuan Hou; Xiangjun Meng; Jinsong Lu; Jianhua Wang
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

Review 10.  Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex.

Authors:  Omeima Abdullah; Ziad Omran; Salman Hosawi; Ali Hamiche; Christian Bronner; Mahmoud Alhosin
Journal:  Genes (Basel)       Date:  2021-04-22       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.